Company news

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news

Apellis Pharmaceuticals, Inc. news releases on 6ix. Latest, Jul 9, 2026: Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI®…

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news

Press releases & updates

Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Apellis Announces Craig Wheeler to Join the Board of Directors

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Apellis Announces Keli Walbert to Join the Board of Directors

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU